Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.54 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11385039 | 0.85 | ADORA2B (0.78) | ADORA2BSMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL11380715 | 0.85 | PDE1A (0.57) | ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL13652738 | 0.85 | PDE4A (0.47) | ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL11378126 | 0.83 | SMN1; SMN2 (0.64) | ADORA2BSMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL13217673 | 0.83 | PDE4A (0.62) | ADORA2BSMN1; SMN2 | |
| SCHEMBL11379379 | 0.82 | ADORA2B (0.62) | ADORA2BSMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL11383083 | 0.82 | SMN1; SMN2 (0.63) | ADORA2BSMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL11312328 | 0.81 | ADORA2B (0.43) | ADORA2BSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL11382208 | 0.81 | SMN1; SMN2 (0.62) | ADORA2BSMN1; SMN2LMNAMAPTMAPK1 | |
| SCHEMBL10432700 | 0.81 | TNF (0.58) | ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4275064-A | Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | claimed |
| US-4061753-A | Treating psoriasis with transient pro-drug forms of xanthine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-12-06 | — | — | US | claimed |
| JP-53098995-A | — | — | None | — | — | JP | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-4275064-A | Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| JP-S5398995-A | TRANSIENT DRUG PRECURSOR AND ITS DRUG COMPOSITION | KANEBO LTD | 1978-08-29 | — | — | JP | disclosed |
| US-4061753-A | Treating psoriasis with transient pro-drug forms of xanthine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | ADORA2B 475/4885SMN1; SMN2 4186/4885LMNA 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.